Biofrontera Inc Cash Flow Conversion Efficiency
Biofrontera Inc cash flow conversion efficiency. Based on the latest financial reports, Biofrontera Inc (BFRI) has a cash flow conversion efficiency ratio of -0.278x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.66 Million) by net assets ($5.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biofrontera Inc (2019–2025)
Cash flow conversion efficiency of Biofrontera Inc from 2019 to 2025. This chart illustrates how Biofrontera Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BFRI live share price for real-time trading data and today's change.
Biofrontera Inc Cash Flow Conversion Ratio Explained
Biofrontera Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biofrontera Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biofrontera Inc ranked by their cash flow conversion efficiency. Also see BFRI stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daesang Corp Preference Shares
KO:001685
|
0.058x |
|
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ:CVKD
|
-1.671x |
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
0.322x |
|
Delorean Corporation Ltd
AU:DEL
|
-0.423x |
|
Wizz Air Holdings PLC
LSE:WIZZ
|
0.897x |
|
Locality Planning Energy Holdings Ltd
AU:LPE
|
-0.094x |
|
Turiya Bhd
KLSE:4359
|
0.023x |
|
nTels Co. Ltd
KQ:069410
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Biofrontera Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Biofrontera Inc from 2019 to 2025. Review free cash flow generation of Biofrontera Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.48 Million | $-13.36 Million | -1.275x | +44.97% |
| 2024-12-31 | $4.43 Million | $-10.27 Million | -2.317x | +55.40% |
| 2023-12-31 | $4.79 Million | $-24.89 Million | -5.194x | -665.62% |
| 2022-12-31 | $23.88 Million | $-16.20 Million | -0.678x | +71.21% |
| 2021-12-31 | $11.34 Million | $-26.71 Million | -2.356x | -11.02% |
| 2020-12-31 | $5.83 Million | $-12.37 Million | -2.122x | -270.00% |
| 2019-12-31 | $-30.18 Million | $-37.68 Million | 1.248x | -- |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more